Sign in with your email address username.


[Comment] Digoxin use in atrial fibrillation: a critical reappraisal

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, affecting more than 33·5 million individuals worldwide.1 Despite pharmacological advances in the past two centuries, digoxin remains the oldest and one of the most common adjunctive treatments for rate control in AF. Although reports show a persistent decrease in overall digoxin prescription rates,2 its use remains common in contemporary AF trials in nearly a third of participants.3